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376ethylenediaminetetraacetic acid-5, 0.1% bovine serum albumin)
either alone or with 5 mmol/l of the V1A selective blocker SR49059.
Incubation was at 25C for 2 h in a volume of 100 ml, and steady-
state kinetics were achieved in speciﬁc binding. The reaction was
terminated with ice-cold incubation buffer and rapid vacuum
ﬁltration through glass ﬁber ﬁlters. Each ﬁlter was washed 3 with
7 ml of ice-cold 10 mmol/l Tris-hydrochloric acid plus 0.1% bovine
serum albumin. Radioactivity was determined in a Gamma counter.
All assays were performed in duplicate. Receptor density was
normalized to membrane protein. The dissociation constant (kd)
and the maximal number of binding sites (Bmax) for
125I-p-AVP
were determined by Scatchard analysis of saturation binding iso-
therms with Graphpad Prism (GraphPad, San Diego, California).
Nonspeciﬁc binding was 30% and was subtracted from total
binding. When using the radio-labeled antagonist speciﬁc for
V1A-R (kd 30 pmol for human recombinant V1A-R), all Scatchard
plots were linear, and the binding curves ﬁt a 1 binding site model.
As seen in Figure 1, the density of V1A-R was signiﬁcantly
increased in failing hearts when compared with nonfailing heart
control subjects without any change in the afﬁnity of the ligand for
the receptor. That the change in density was due to an increase in
receptor expression was supported by the fact that there was a
comparable increase in the levels of the messenger ribonucleic acid
encoding V1A-R (Fig. 1). This represents the ﬁrst report demon-
strating changes in V1A-R expression in HF. The majority of the
patients were receiving inotropic therapy, and therefore our ﬁndings
might not be generalizable to patients with less severe disease.
Interestingly, our ﬁndings are in contrast with the decrease in the
expression of b1-adrenergic and angiotensin type 1 receptors that
characterize the failing human heart (4). Further studies will be
required to better understand the molecular mechanisms responsible
for this difference as well as to determine whether these changes in
receptor density contribute to diminished cardiac function observed
in patients with end-stage HF and elevated the levels of AVP.Weizhong Zhu, MD, PhD
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1381–2.Letters to the Editor
Same-Day Discharge After
Percutaneous Coronary Intervention
Trial Sequential Analysis of Outcomes
In the comparison made between same-day discharge and routine
overnight observation by Brayton et al. (1), the best level of evi-
dence was that derived from randomized controlled trial (RCT)
studies. With regard to the composite outcome of death, myocar-
dial infarction, or target lesion revascularization, the analysis of
7 RCTs showed no signiﬁcant differences between the 2 ap-
proaches (pooled odds ratio: 0.90; 95% conﬁdence interval: 0.43 to
1.87; p ¼ 0.78). While this result supports the conclusion of no
proven difference, the main question is whether or not the available
data support a conclusion in terms of proof of no difference (or
proof of noninferiority) rather than the mere demonstration of no
proof of difference.
One problem in exploring these methodological questions is that
the degree of consensus on how noninferiority meta-analysis can be
conducted is still modest (2). On the other hand, the advantages of
trial sequential analysis (TSA) are being recognized increasingly
not only for handling questions of superiority (3,4) but also with
regard to those of noninferiority (3–5); in fact, TSA aims at clas-
sifying each meta-analysis into one of only 4 categories (superiority,
inferiority, futility/noninferiority, inconclusive result).
We applied TSA to the same 7 RCTs examined by Brayton et al.
(1). Our assumptions included 2-sided testing, type 1 error of 5%, and
a power of 80%. With respect to the above-mentioned composite
outcome, the intervention effect was set at a relative risk reduction
(RRR) of 50%or 33%.The expected absolute event rate in the controls
was 7.6% (i.e., the cumulative arithmetic rate in the control groups of
the 7RCTs).Themain result ofTSAwasexpressed through the graph
of a cumulative z-curve; the boundaries in this graph for concluding
superiority or inferiority or futility were determined according to the
O’Brien–Fleming alpha-spending function. All calculations were
carried out using a speciﬁc statistical software (User Manual for TSA,
TSA, Copenhagen Trial Unit 2011).
Our results are shown in Figure 1. The number of events
recorded in the RCTs proved to be insufﬁcient to construct the
boundaries of futility in both analyses; in addition, the statisti-
cal procedure incorporated only 6 RCTs because one trial
Figure 1
Trial Sequential Analysis of 6 RCTs Comparing Same-Day
Discharge With Routine Overnight Observation After
Percutaneous Coronary Intervention
The expected relative risk reduction (RRR) was assumed to be 50% (A) or 33% (B).
In the z-curve (blue), individual trials correspond to individual segments; trials are
plotted in chronological order (from left to right). The x-axis indicates the cumu-
lative number of patients; the starting point of the z-curve is always at x ¼ 0,
that is, inclusion of no trials. C ¼ control arm (routine overnight observation);
RCT ¼ randomized controlled studies; T ¼ treatment arm (same-day discharge);
red lines are the boundaries for superiority or inferiority.
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377(characterized by zero-event frequency in both arms) was unin-
formative according to the TSA statistical algorithm.
Our results indicate that current information from RCTs does
not allow us to draw any ﬁrm conclusion about the outcome
comparison between the two approaches (i.e., “inconclusive result”
of TSA). In fact, while the overall number of patients enrolled in
the 6 trials was 2,555, our TSA estimated that the optimal
information size would be 10,752 patients (assuming RRR ¼ 50%)
or 27,243 patients (assuming RRR ¼ 33%).
In summary, the number of patients studied in the RCTs pres-
ently available is only one-fourth or one-tenth in comparison with
the ideal sample size required to draw a ﬁrm conclusion. Therefore,
the comparison between the 2 discharge strategies remains open.*Andrea Messori, PharmD
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2013;173:1466–8.Statistical Uncertainty in
10-Year Framingham Risk of
Coronary Heart Disease and
Cardiovascular Disease
In a recent study, Ford (1) presents an important analysis, with
implications for public health prioritization. However, we believe
some of the ﬁndings should be interpreted with caution. The
Framingham Heart Study has contributed immeasurably to our
understanding of cardiovascular disease in the United States
and internationally, but the published regression equations for
10-year risk of coronary heart disease (CHD) and cardiovascular
disease (CVD) were developed for clinical use, and variance-
covariance matrices were not reported (2,3). Thus, it is
impossible to quantify uncertainty or estimate conﬁdence in-
tervals for any patient’s 10-year risk of CHD or CVD. In other
words, while the mean of the risk is known, its variance is
unknown.
For this reason, the standard errors for the population-level
10-year risk of CHD and CVD that Ford (1) presents in Ta-
ble 1 in his article are misleading. The same method is used to
estimate these standard errors as used for measures such as age,
blood pressure, and cholesterol level. The difference between them
is that, unlike Framingham risk scores, these characteristics can be
measured with certainty (or are assumed to be measured with
negligible error and thus are treated as “certain”); thus, their stan-
dard errors are appropriate and accurate. On the other hand, the
standard errors reported for population-level 10-year risk of CHD
and CVD are inappropriate because they capture only between-
person variability in predicted risk but do not account for the fact
